|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1999-10-28
|
|
pubmed:abstractText |
Intravenous immunoglobulins (IVIg) therapy has been reported to be beneficial in a large number of autoantibody-mediated or self-reactive T cells-associated autoimmune diseases. Thus, the beneficial effect of IVIg is probably due to multiple distinct mechanisms.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0248-8663
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20 Suppl 4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
423s-430s
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10522317-Apoptosis,
pubmed-meshheading:10522317-Autoantibodies,
pubmed-meshheading:10522317-Autoimmune Diseases,
pubmed-meshheading:10522317-Cytokines,
pubmed-meshheading:10522317-Humans,
pubmed-meshheading:10522317-Immunoglobulins, Intravenous,
pubmed-meshheading:10522317-Lymphocytes,
pubmed-meshheading:10522317-Monocytes,
pubmed-meshheading:10522317-Receptors, Fc,
pubmed-meshheading:10522317-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
[Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases].
|
|
pubmed:affiliation |
Inserm U430, Hôpital Broussais, Paris.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
